All In Biotech

Drug Trial Radar · NCT06625242

A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis

A Multicenter, Open-label, Single-arm, Phase 4 Study to Evaluate the Efficacy and Safety of Filgotinib in Korean Patients With Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

118

Actual

Start

Oct 22, 2024

Primary completion

Jan 21, 2026

Study completion Feb 25, 2026

Sponsor

Lead sponsor
Eisai Korea Inc.Eisai
Sponsor type
Industry
First posted
Oct 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to assess the percentage of participants achieving an American College of Rheumatology (ACR) 20 percent (%) Improvement (ACR20) response at Week 12 of the administration of the investigational product.

Conditions

  • Rheumatoid Arthritis

Interventions

  • Filgotinib MaleateDrug

    Administered as oral tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving ACR20 Response at Week 12Time frame: At Week 12

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Eisai site #11

    Anyang-si, South Korea

  • Eisai site #01

    Busan, South Korea

  • Eisai site #09

    Daegu, South Korea

  • Eisai site #12

    Daegu, South Korea

  • Eisai site #06

    Daejeon, South Korea

  • Eisai site #15

    Guri-si, South Korea

  • Eisai site #02

    Gwangju, South Korea

  • Eisai site #13

    Incheon, South Korea

  • Eisai site #03

    Seoul, South Korea

  • Eisai site #04

    Seoul, South Korea

  • Eisai site #05

    Seoul, South Korea

  • Eisai site #07

    Seoul, South Korea

  • Eisai site #08

    Seoul, South Korea

  • Eisai site #10

    Seoul, South Korea

  • Eisai site #14

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.